Cas:402470-91-1 N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide manufacturer & supplier

Chemical Name:N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide

CAS.NO:402470-91-1

Synonyms:N,N-Dimethyl-4-(4-methylphenyl)-4-oxobutanamide

Molecular Formula:C₁₃H₁₇NO₂

Molecular Weight:219.28000

HS Code:2924299090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:37.38000

Exact Mass:219.12600

LogP:2.04610

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N,N-Dimethyl-4-(4-methylphenyl)-4-oxobutanamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-Dimethyl-4-(4-methylphenyl)-4-oxobutanamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N-Dimethyl-4-(4-methylphenyl)-4-oxobutanamide Use and application,N,N-Dimethyl-4-(4-methylphenyl)-4-oxobutanamide technical grade,usp/ep/jp grade.

Related News: As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide manufacturer The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace. N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide supplier In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide vendor Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. N,N-Dimethyl-4-oxo-4-(p-tolyl)butanamide factory As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy.